Welcome to Paid Research Studies




  • Condition:   Herpes Zoster
    Intervention:   Other: Encoding of data collected in Zoster 006 and Zoster 022 studies
    Sponsor:   GlaxoSmithKline
    Recruiting

  • Conditions:   Rheumatoid Arthritis;   Psoriatic Arthritis;   Ankylosing Spondylitis
    Interventions:   Biological: Originator;   Biological: Biosimilar
    Sponsors:   Opal Rheumatology Ltd.;   Merck Sharp & Dohme Corp.
    Recruiting

  • Condition:   Diffuse Cutaneous Systemic Sclerosis
    Interventions:   Drug: Lenabasum 5 mg;   Drug: Lenabasum 20 mg;   Other: Placebo oral capsule
    Sponsor:   Corbus Pharmaceuticals Inc.
    Recruiting

  • Conditions:   Systemic Lupus Erythematosus;   Lupus Nephritis
    Interventions:   Drug: KZR-616;   Drug: Placebo
    Sponsor:   Kezar Life Sciences, Inc.
    Recruiting

  • Conditions:   Diabetes;   Diabetes Mellitus, Type 1
    Interventions:   Drug: Insulin degludec;   Drug: Insulin Aspart;   Drug: Insulin detemir
    Sponsor:   Novo Nordisk A/S
    Recruiting

  • Condition:   IgA Nephropathy
    Interventions:   Drug: LNP023;   Drug: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Agglutinin Disease, Cold
    Intervention:   Drug: Sutimlimab
    Sponsor:   Bioverativ Therapeutics Inc.
    Recruiting

  • Condition:   Agglutinin Disease, Cold
    Interventions:   Drug: Sutimlimab;   Drug: Placebo
    Sponsor:   Bioverativ Therapeutics Inc.
    Recruiting

  • Conditions:   Relapsing Remitting Multiple Sclerosis;   Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
    Intervention:   Biological: ATA188
    Sponsor:   Atara Biotherapeutics
    Recruiting

  • Conditions:   Rheumatoid Arthritis;   Stiffness, Aortic;   Endothelial Dysfunction;   Cardiovascular Risk Factor
    Interventions:   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Other DMARDs
    Sponsors:   Flinders University;   University of South Australia;   medac GmbH
    Recruiting

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Biological: SYN060;   Biological: Adalimumab North American source;   Biological: Adalimumab European source
    Sponsor:   Synermore Biologics Co., Ltd.
    Recruiting

  • Condition:   Multiple Sclerosis
    Interventions:   Drug: BIIB033 (opicinumab);   Drug: Placebo
    Sponsor:   Biogen
    Recruiting

  • Condition:   Systemic Lupus Erythematosus
    Intervention:  
    Sponsors:   Monash University;   Flinders Medical Centre, Adelaide, AUSTRALIA;   St. Vincent's Hospital, Melbourne, AUSTRALIA;   Royal Adelaide Hospital, Adelaide, AUSTRALIA;   University of New South Wales, Sydney, AUSTRALIA;   People's Hospital, Peking University Health Science Center, Beijing, CHINA;   Peking University First Hospital, Beijing, CHINA;   The University of Hong Kong, HONG KONG;   University of Padjadjaran, Bandung, INDONESIA;   Tokyo Women's Medical University, JAPAN;   University of Occupational and Environmental Health, JAPAN;   Keio University, JAPAN;   Hanyang University Hospital for Rheumatic Diseases, REPUBLIC OF KOREA;   University of Malaya;   University of Santo Tomas Hospital, Philippines;   National University Hospital, Singapore;   Tan Tock Seng Hospital;   Chang Gung Memorial Hospital;   Taichung Veterans General Hospital;   Chiang Mai University Hospital, THAILAND;   Dubai Hospital, Dubai, UNITED ARAB EMIRATES;   Middlemore Hospital, New Zealand;   North Shore Hospital, Auckland, NEW ZEALAND;   Auckland District Health Board, Auckland, NEW ZEALAND
    Recruiting

  • Condition:   Multiple Sclerosis, Relapsing-Remitting
    Intervention:   Drug: Ocrelizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Condition:   Rheumatoid Arthritis (RA)
    Interventions:   Drug: Upadacitinib matching placebo;   Drug: Abatacept matching placebo;   Drug: Upadacitinib;   Drug: Abatacept
    Sponsor:   AbbVie
    Recruiting

  • Condition:   Diabetes Mellitus
    Interventions:   Other: Novel diet;   Other: Standard diet
    Sponsor:   Garvan Institute of Medical Research
    Recruiting

  • Condition:   Active Systemic Lupus Erythematosus
    Interventions:   Biological: Anifrolumab;   Drug: Placebo
    Sponsors:   AstraZeneca;   PRA Health Sciences
    Recruiting

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: CP-690,550;   Drug: Methotrexate;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Rheumatoid Arthritis Interstitial Lung Disease
    Interventions:   Drug: Pirfenidone;   Drug: Placebo
    Sponsor:   Ivan O. Rosas
    Recruiting

  • Condition:   Relapsing Multiple Scelrosis
    Interventions:   Drug: Ofatumumab subcutaneous injection;   Drug: Placebo orally matching to teriflunomide;   Drug: Teriflunomide orally;   Drug: Placebo subcutaneous injection matching to ofatumumab
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Lupus Nephritis
    Interventions:   Drug: BI 655064 dose 1;   Drug: BI 655064 dose 2;   Drug: BI 655064 dose 3;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting

  • Condition:   Autoimmune Pulmonary Alveolar Proteinosis
    Interventions:   Drug: molgramostim;   Drug: placebo
    Sponsor:   Savara Inc.
    Recruiting

  • Condition:   Pemphigus Vulgaris
    Intervention:   Drug: PRN1008
    Sponsors:   Principia Biopharma, Inc.;   Principia Biopharma Australia Pty Ltd.
    Recruiting

  • Condition:   Thrombocytopenia
    Intervention:   Drug: UCB7665
    Sponsors:   UCB Biopharma S.P.R.L.;   Parexel
    Recruiting

  • Conditions:   Urinary Incontinence;   Overactive Bladder
    Interventions:   Drug: AbobotulinumtoxinA;   Drug: AbobotulinumtoxinA Placebo
    Sponsor:   Ipsen
    Recruiting

  • Condition:   Juvenile Idiopathic Arthritis
    Interventions:   Drug: CP-690,550 (tofacitinib);   Other: placebo
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Lupus Nephritis
    Interventions:   Biological: Anifrolumab;   Drug: Placebo
    Sponsors:   AstraZeneca;   Parexel
    Recruiting

  • Condition:   Safety LTFU, Pts Receiving CD19 Directed CAR T-Cell Therapy
    Intervention:   Genetic: Previously treated CART CD 19 patients
    Sponsors:   Novartis Pharmaceuticals;   University of Pennsylvania
    Recruiting

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: tofacitinib;   Biological: adalimumab;   Biological: etanercept
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Multiple Sclerosis
    Intervention:   Drug: dimethyl fumarate
    Sponsor:   Biogen
    Recruiting

  • Conditions:   Multiple Sclerosis;   Exposure During Pregnancy
    Interventions:   Drug: Dimethyl fumarate;   Drug: Peginterferon beta-1a
    Sponsor:   Biogen
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Condition:   IgA Glomerulonephritis
    Interventions:   Drug: methylprednisolone;   Drug: Placebo
    Sponsors:   The George Institute;   Peking University First Hospital
    Recruiting

  • Condition:   Juvenile Idiopathic Arthritis
    Intervention:   Drug: Tofacitinib
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Multiple Sclerosis
    Interventions:   Drug: other disease-modifying therapy;   Drug: Fingolimod
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Multiple Sclerosis
    Intervention:   Drug: Fingolimod
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Relapsing-Remitting Multiple Sclerosis
    Intervention:   Drug: natalizumab
    Sponsor:   Biogen
    Recruiting

  • Condition:   Diabetes Mellitus, Type 1
    Intervention:  
    Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Allergy and Infectious Diseases (NIAID);   National Center for Research Resources (NCRR);   Juvenile Diabetes Research Foundation;   American Diabetes Association
    Recruiting